Resumen de Surveillance for Recurrence of Colorectal Cancer
In interpreting the results of a randomized clinical trial comparing different surveillance strategies after curative resection of colorectal cancer, Dr Primrose and colleagues1 suggested that “stage-specific follow-up strategies may not be necessary” because “although there are fewer recurrences with better-stage tumors, they are more likely to be curable.” This suggestion is not consistent with the current National Comprehensive Cancer Network (NCCN) guidelines and the American Society of Clinical Oncology (ASCO) practice guidelines. The NCCN recommends intensive surveillance with annual enhanced computed tomography (CT) along with serum carcinoembryonic antigen (CEA) measurement every 3 to 6 months only for patients with stage III colon cancer.2 The ASCO panel mentions that other than stage and subset, there is no single pathological feature or statistical model that can be used to build a surveillance strategy.3
